United Therapeutics (UTHR) Change in Receivables (2009 - 2026)

United Therapeutics has disclosed Change in Receivables across 18 years of filings, most recently posting -$1.7 million for Q2 2026.

• In Q2 2026, Change in Receivables fell 102.97% year-over-year to -$1.7 million; the TTM figure through Jun 2026 stood at -$69.0 million (down 177.88% YoY), while the FY2025 annual figure was $70.9 million, up 17625.0% from the prior year.
• Change in Receivables came in at -$1.7 million for Q2 2026 at United Therapeutics, up from -$38.2 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $138.1 million in Q2 2023 to a low of -$85.9 million in Q1 2023.
• Average Change in Receivables over 5 years is $6.2 million, with a median of $550000.0 recorded in 2022.
• Year-over-year, Change in Receivables surged 4832.14% in 2023 and slumped 407.88% in 2024.
• Over 5 years, Change in Receivables stood at -$11.3 million in 2022, then surged by 279.65% to $20.3 million in 2023, then tumbled by 407.88% to -$62.5 million in 2024, then jumped by 184.0% to $52.5 million in 2025, then sank by 103.24% to -$1.7 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were -$1.7 million in Q2 2026, -$38.2 million in Q1 2026, and $52.5 million in Q4 2025.